5 Dirt-Cheap Healthcare Stocks With Big Dividends To Buy Now

Photo of Lee Jackson
By Lee Jackson Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
5 Dirt-Cheap Healthcare Stocks With Big Dividends To Buy Now

© tupungato / iStock Editorial via Getty Images

While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and likely 2024. Demand is growing as the country ages; pricing remains solid and plain and straightforward; it is one sector that never goes out of style as cyclical swings don’t hit it.

We screened our 24/7 Wall St. healthcare research database, looking for the highest-paying dividend leaders rated buy across Wall Street. Five companies that are all excellent players in the industry came up, and all make good sense for growth and income investors looking for solid total return ideas.

Amgen

JHVEPhoto / iStock Editorial via Getty Images

This biotech giant remains a top stock for investors to buy and a safer way to play the massive potential growth in biosimilars. Amgen Inc. (NASDAQ: AMGN | AMGN Price Prediction) discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Investors are paid a solid 3.15% dividend.

The company’s products include:

  • Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis
  • Neulasta reduces the chance of infection due to a low white blood cell count in patients with cancer
  • Prolia to treat postmenopausal women with osteoporosis
  • Xgeva for skeletal-related events prevention
  • Otezla for treating adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet’s disease
  • Aranesp to treat a lower-than-normal number of red blood cells and anemia
  • KYPROLIS to treat patients with relapsed or refractory multiple myeloma
  • Repatha reduces the risks of myocardial infarction, stroke, and coronary revascularization

Gilead Sciences

Sundry Photography / iStock Editorial via Getty Images

This company is trading at a very reasonable 11 times estimated 2023 earnings, has big-time upside potential, and a rich 3.70% dividend. Gilead Sciences, Inc. (NASDAQ: GILD), a research-based biopharmaceutical company, discovers, develops, and commercializes medicines for unmet medical needs in the United States, Europe, and internationally.

The company provides

  • Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection
  • Veklury, an injection for intravenous use for the treatment of coronavirus disease 2019
  • Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for treating liver diseases
  • Yescarta, Tecartus, Trodelvy, and Zydelig products for treating hematology, oncology, and cell therapy patients

In addition, Gilead provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of severe invasive fungal infections.

Merck

Michael Vi / iStock Editorial via Getty Images

This company remains a leading healthcare stock for conservative investors who are paid a dependable 2.80% dividend. Merck & Co. Inc. (NYSE: MRK) is a healthcare company worldwide.

Merck operates through two segments: Pharmaceutical and Animal Health.

  • The Pharmaceutical segment offers human health pharmaceutical products in oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
  • The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.

Merck serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.

The company collaborates with AstraZeneca PLC, Bayer AG; Eisai Co., Ltd., Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV.

Pfizer

Nathan Howard / Getty Images News via Getty Images

This top pharmaceutical stock was one of the biggest winners in the ongoing COVID-19 vaccine sweepstakes; with that revenue subsiding, the sellers have crushed the stock. Pfizer Inc. (NYSE: PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Investors with a long-time horizon will receive a massive 5.26% dividend.

  • The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands.
  • Biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands
  • Sterile injectable and anti-infective medicines and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands

Pfizer also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19.

  • Under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba
  • Biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands
  • Amyloidosis, hemophilia, and endocrine disorders under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands

Sanofi

HJBC / iStock Editorial via Getty Images

This is a top pharmaceutical company in Europe, trading reasonably and paying a massive 4.20% dividend. Sanofi (NYSE: SNY) engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally.

Sanofi operates through three segments:

  • Pharmaceuticals
  • Vaccines
  • Consumer Healthcare

The company provides specialty care products, including:

  • Human monoclonal antibodies
  • Products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders
  • Medicines for diabetes and cardiovascular and established prescription products
  • It also supplies poliomyelitis, pertussis, Hib pediatric vaccines, influenza, adult booster, meningitis, and travel and endemic vaccines.

In addition, Sanofi offers allergy, cough, cold, pain, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. It also has various pharmaceutical products and vaccines in the development stage.

Photo of Lee Jackson
About the Author Lee Jackson →

Lee Jackson has covered Wall Street analysts' equity and debt research and equity strategy daily for 24/7 Wall St. since 2012. His broad and diverse career, which included a stint as the creative services director at the NBC affiliate in Austin, Texas, gives him unique insight into the financial industry and world.

Lee Jackson's journey in the financial industry spans over 30 years, with nearly two decades as an institutional equity salesperson at Bear Stearns, Lehman Brothers, and Morgan Stanley. His career was marked by his presence on the sell side during pivotal Wall Street events, from the dot.com rise and bubble to the Long Term Capital Management debacle, 9/11, and the Great Recession of 2008. This is a testament to his resilience and adaptability in the face of market volatility.

Lee Jackson’s practical financial industry experience, acquired from a career at some of the biggest banks and brokerage firms, is complemented by a lifetime of writing on various platforms. This unique combination allows him to shed light on the intricacies and workings of Wall Street in a way that only someone with deep insider experience and knowledge can. Moreover, his extensive network across Wall Street continues to provide direct access for him and 24/7 Wall St., a privilege few firms enjoy.

Since 2012, Jackson’s work for 24/7 Wall St. has been featured in Barron’s, Yahoo Finance, MarketWatch, Business Insider, TradingView, Real Money, The Street, Seeking Alpha, Benzinga, and other media outlets. He attended the prestigious Cranbrook Schools in Bloomfield Hills, Michigan, and has a degree in broadcasting from the Specs Howard School of Media Arts.

Continue Reading

Top Gaining Stocks

DDOG Vol: 25,984,860
FTNT Vol: 18,110,087
AXON Vol: 2,560,582
PAYC Vol: 2,186,532
VTRS Vol: 34,754,321

Top Losing Stocks

ZTS Vol: 29,987,605
TPR Vol: 6,457,816
CTRA Vol: 73,319,495
TER Vol: 5,001,462
JBL Vol: 1,753,464